These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33778924)

  • 21. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
    Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
    Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus.
    Choi JW; Kim HC; Lee JH; Yu SJ; Kim YJ; Yoon JH; Jae HJ; Hur S; Lee M; Chung JW
    Eur Radiol; 2017 Apr; 27(4):1448-1458. PubMed ID: 27516356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
    Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
    AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
    [No Abstract]   [Full Text] [Related]  

  • 26. Survival benefit of radiofrequency ablation for solitary (3-5 cm) hepatocellular carcinoma: An analysis for nationwide cancer registry.
    Lee SH; Jin YJ; Lee JW
    Medicine (Baltimore); 2017 Nov; 96(44):e8486. PubMed ID: 29095307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
    Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
    AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting Outcomes After Chemo-Embolization in Patients with Advanced-Stage Hepatocellular Carcinoma: An Evaluation of Different Radiologic Response Criteria.
    Gunn AJ; Sheth RA; Luber B; Huynh MH; Rachamreddy NR; Kalva SP
    Cardiovasc Intervent Radiol; 2017 Jan; 40(1):61-68. PubMed ID: 27834009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma.
    Labeur TA; Takkenberg RB; Klümpen HJ; van Delden OM
    Cardiovasc Intervent Radiol; 2019 Feb; 42(2):230-238. PubMed ID: 30488302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
    Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
    Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
    Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
    J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Barman PM; Sharma P; Krishnamurthy V; Willatt J; McCurdy H; Moseley RH; Su GL
    Dig Dis Sci; 2014 Nov; 59(11):2821-5. PubMed ID: 24973040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.
    Yang B; Zheng B; Yang M; Zeng Z; Yang F; Pu J; Li C; Liao Z
    Hepatol Int; 2018 Sep; 12(5):417-428. PubMed ID: 30073454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival.
    Mouli SK; Hickey R; Thornburg B; Sato KT; Desai K; Gabr A; Kallini JR; Niemeri H; Kircher S; Mulcahy MF; Benson Iii AB; Gupta R; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1279-1287. PubMed ID: 27062355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.
    Adhoute X; Pénaranda G; Raoul JL; Pietri O; Bronowicki JP; Castellani P; Perrier H; Monnet O; Bayle O; Oules V; Pol B; Beaurain P; Muller C; Cassagneau P; Bourlière M
    Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1414-1423. PubMed ID: 31045613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma.
    Lin H; Wu H; Cong N; Liu B; Liu C; Han D
    Technol Cancer Res Treat; 2020; 19():1533033820983799. PubMed ID: 33357168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.